Biblio
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15(1):615.
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023.
Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma. Transplant Cell Ther. 2023.
Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022.
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020;4(19):4834-4837.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115.
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2018.
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2018.